Kymera Therapeutics, Inc. (KYMR) Debt-to-equity % [USD] 2021 - 2024

Historical data

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Kymera Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from 2021 to 2024.
Kymera Therapeutics, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 33.1 %, a 19.5% increase year-over-year.

Debt-to-equity, Quarterly (% [USD])

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q1 2024	33.1	+5.41	+19.5%	Mar 31, 2024
Q4 2023	37.7	+10.4	+38.3%	Dec 31, 2023
Q3 2023	31.9	+2.32	+7.85%	Sep 30, 2023
Q2 2023	28.3	-3.7	-11.6%	Jun 30, 2023
Q1 2023	27.7	-10.1	-26.8%	Mar 31, 2023
Q4 2022	27.2	-18.2	-40.1%	Dec 31, 2022
Q3 2022	29.6	-26.5	-47.2%	Sep 30, 2022
Q2 2022	32	-38.3	-54.5%	Jun 30, 2022
Q1 2022	37.8			Mar 31, 2022
Q4 2021	45.5			Dec 31, 2021
Q3 2021	56			Sep 30, 2021
Q2 2021	70.3			Jun 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.